Cited by 278Antifungal resistance and susceptibilityLipid Membrane Structure and BehaviorFungal and yeast genetics research

The Multifunctional Fungal Ergosterol

Open access
Rodrigues, Marcio L.·2018·mBio

Abstract

The roles of ergosterol in the regulation of membrane fluidity and structure, as well its role as a target for the activity of antifungals, have been known for decades. Two recent studies, however, demonstrated that ergosterol is an immunologically active lipid that induces pyroptosis and that virtually all steps of its biosynthetic process are potential drug targets.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/mbio.01755-18

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Ergosterol biosynthesis pathway has been identified as traditional therapeutic target for invasive candidiasis.

    “The ergosterol biosynthesis pathway has been identified as a traditional therapeutic target for addressing invasive candidiasis55.”

    From Impairing the interaction between Erg11 and cytochrome P450 reductase Ncp1 enhances azoles’ antifungal activities (2025) · cites this paper as [55]

    The section “ERGOSTEROL BIOSYNTHESIS PATHWAYS PROVIDE MULTIPLE TARGETS FOR ANTIFUNGAL DEVELOPMENT” says ergosterol biosynthesis is an established target of antifungal compounds and identifies existing drug classes that inhibit it. It discusses systemic mycoses generally, but does not specifically identify the pathway as a therapeutic target for invasive candidiasis. (LLM, conf=0.83)

    Experimental — accuracy not yet measured
  • Other studies mentioned that the antifungal activities of ATO and other statin drugs can be attributed to the inhibition of ergosterol and isoprenoid-biosynthesis.

    “Other studies mentioned that the antifungal activates of ATO and other statin drugs can be attributed to the inhibition of ergosterol and isoprenoid-biosynthesis are thought to result in these antifungal properties (Rahal et al. 2015; Rodrigues 2018; Lima et al. 2019)”

    From In vitro study on the potential fungicidal effects of atorvastatin in combination with some azole drugs against multidrug resistant Candida albicans (2021) · cites this paper as Rodrigues 2018

    The section “Ergosterol Biosynthesis Pathways Provide Multiple Targets for Antifungal Development” links lovastatin’s antifungal activity to genes in the ergosterol-biosynthesis pathway. It does not mention atorvastatin (ATO) or attribute statins’ antifungal activity to inhibition of isoprenoid biosynthesis; the claim therefore exceeds what this source supports. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rodrigues, M. L.
Affiliations
Instituto Carlos Chagas, Fundação Oswaldo Cruz (Fiocruz), Curitiba, Brazil
Venue
mBio
Published
2018-11-07
Volume
9
Issue
5
ISSN
  • 2150-7511 (ISSN-L)
  • 2161-2129
OpenAlex
W2890570825
Cited by
275
References
20
Citations by year
2026: 36 · 2025: 58 · 2024: 40 · 2023: 42 · 2022: 32 · 2021: 32 · 2020: 26 · 2019: 9
FWCI
12.65
Type
journal article
Language
en
Open access
Locations
  • mBio (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • MCTI | Conselho Nacional de Desenvolvimento Científico e Tecnológico (443586/2014-4)
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (E-26/202.997/2015)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Lipid Membrane Structure and Behavior
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
Keywords
ergosterol, fungal cell membrane, membrane fluidity, antifungal drug targets, ergosterol biosynthesis, pyroptosis, fungal immunology
MeSH terms
Pyroptosis, Antifungal Agents, Candida albicans, Ergosterol, Macrophages, Microbial Sensitivity Tests, Saccharomyces cerevisiae

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review